市場調查報告書

胰臟癌症的治療及診斷的全球市場:成長,趨勢,及預測(2019年∼2024年)

Pancreatic Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 353881
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
Back to Top
胰臟癌症的治療及診斷的全球市場:成長,趨勢,及預測(2019年∼2024年) Pancreatic Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 112 Pages
簡介

本報告提供全球胰臟癌症的治療及診斷市場的相關調查,提供市場機會和課題,成長及阻礙因素,治療方法·診斷方法·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各治療方法
    • 標靶治療
    • 化療
    • 手術
    • 其他
  • 各診斷方法
    • 影像
    • 切片檢查
    • 內視鏡檢驗
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲地區
    • 南美

第6章 競爭情形

  • 公司概要
    • Apex Medical Corp.
    • Chart Industries Inc.
    • Devilbiss Healthcare LLC
    • Fisher & Paykel
    • GE Healthcare
    • Intersurgical Ltd
    • Invacare Corporation
    • Medtronic PLC
    • Philips Healthcare
    • ResMed

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52022

Market Overview

Pancreatic cancer is the 12th most common cancer in the world. The estimated five-year prevalence of people living with pancreatic cancer is 4.1 per 100,000, globally. This cancer is almost always fatal and is the seventh most common cause of death from cancer. Pancreatic cancer is closely related to body fat and high BMI, thereby being more prevalent in the developed countries. A report by the Centers for Disease Control and Prevention (CDC) estimated that pancreatic cancer resulted in the death of about 330,000 people in 2012 in the United States, which was around 4% of all deaths in the country. Estimates of the American Cancer Society suggested that in the United States alone, nearly 53,070 new cases of pancreatic cancer were recorded in 2016 and 41,780 deaths in the country were attributed to the same. In Europe, nearly 104,000 new cases of pancreatic cancer were estimated to be diagnosed in 2012. The extensive threat of pancreatic cancer is a major opportunity for companies to capitalize on the market through the expansion of product portfolios and market penetration. The high patient pool and increasing trends of the same are expected to propel the growth of the market.

Scope of the Report

Pancreatic cancer occurs when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine, based on the cells affected by cancer. Exocrine cells in pancreas create pancreatic enzymes. When cancer manifests in these cells, it is referred to as exocrine pancreatic cancer. Endocrine cells are a small cluster of cells and also called 'islets of Langerhans'. These cells create hormones, such as insulin and glucagon, releasing them into the blood flow. Cancer in these cells is called endocrine pancreatic cancer.

Key Market Trends

Targeted Therapy Segment is expected to exhibit fastest growth rate over the forecast period

Pancreatic cancer therapeutics is basically classified into chemotherapy, surgery, targeted therapy, and others. The targeted therapy segment is expected to witness the fastest growth rate over the forecast period owing to the higher efficacy, increasing rate of innovations, and speedy drug approvals. Targeted therapy can be referred to as the treatment with the use of drugs or other biochemical substances in order to identify and target specific cancerous cells with no or minimal harm to the healthy cells surrounding the cancer cell. For instance, Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy drugs that block the activity of cell growth in the cancerous cells. Erlotinib is an example of TKI used in targeted therapy for the treatment of pancreatic cancer.

North America dominated the overall market and is expected to retain its dominance

North America dominated the pancreatic cancer therapeutics and diagnostics market. In the United States, the average lifetime risk of pancreatic cancer for both men and women is about 1 in 65 (1.5%). Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of cancer deaths. The Pancreatic Cancer Action Network predicts pancreatic cancer to become the second leading cause of cancer-related deaths in the United States, by 2020. With promising drugs in the pipeline, the US pancreatic cancer therapeutics and diagnostics market is expected to witness lucrative growth during the forecast period. The high healthcare spending and state-of-the-art healthcare facilities in the United States are expected to promote the growth of the market, indirectly. The country is also a hub for high-end R&D activities, which are anticipated to have a positive impact on the novel product developments and clinical trials.

Competitive Landscape

The presence of major market players, such as Amgen, Eli Lilly, F. Hoffmann La-Roche, Novartis, and Pfizer, among others is intensifying the competition. The market players are adopting strategies, such as rising R&D investments, mergers, acquisitions, and product innovations in order to sustain the increasing market rivalry.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
    • 4.2.2 Chronic Nature of Diseases Leads to Consistent Demand for Drugs
    • 4.2.3 Advancements in Molecular Biology, Development of Drugs, and Diagnostic Technology
    • 4.2.4 Emphasis on Early Diagnosis
  • 4.3 Market Restraints
    • 4.3.1 Drug Toxicity and Side Effects
    • 4.3.2 Drugs Losing Patent Exclusivity
    • 4.3.3 High Costs Associated with Diagnosis and Treatments
    • 4.3.4 Stringent Regularly Guidelines
  • 4.4 Porters Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapeutics
    • 5.1.1 Targeted Therapies
    • 5.1.2 Chemotherapy
    • 5.1.3 Surgery
    • 5.1.4 Other Therapeutics
  • 5.2 Diagnostics
    • 5.2.1 Imaging
    • 5.2.2 Biopsy
    • 5.2.3 Endoscopy
    • 5.2.4 Other Diagnostics
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 UK
      • 5.3.2.2 Germany
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Apex Medical Corp.
    • 6.1.2 Chart Industries Inc.
    • 6.1.3 Devilbiss Healthcare LLC
    • 6.1.4 Fisher & Paykel
    • 6.1.5 GE Healthcare
    • 6.1.6 Intersurgical Ltd
    • 6.1.7 Invacare Corporation
    • 6.1.8 Medtronic PLC
    • 6.1.9 Philips Healthcare
    • 6.1.10 ResMed

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top